Tagged with OP

Japan Toshio Fujimoto, MBA, MD of Japan’s Shonan Health Innovation Park explores new ways of virtual collaboration that make our lives easier while enabling us to maintain a culture of innovation and growth.   Are social distancing requirements causing the life science industry to return to an inward-looking culture of secrecy?…

Sanofi With former head David Loew moving to the CEO position at Ipsen, Sanofi appointed French national Thomas Triomphe as the new head of its vaccines business unit, Sanofi Pasteur, on June 15th 2020.    Under the watch of CEO Paul Hudson, appointed at the end of 2019, Sanofi has initiated…

Data New approaches to pharma sales: Marrying data analytics with the art of personal engagement   The lock-down impact for COVID-19 was stark, looking at available March data cuts from IQVIA which signal serious additional healthcare consequences beyond infected patients. A decline of 72% of in-person doctor visits, -70% Rx volume,…

Europe In conversation with PharmaBoardroom Christoph Stoller and Adrian Van den Hoven of Medicines for Europe, the association representing the European generics, biosimilar and value-added-medicines industry, highlighted their members’ rapid response to the COVID-19 crisis and why Europe-wide reform is needed to avoid future medicine shortages and strengthen the supply chain.…

USA Ulrich Neumann examines the debate around drug pricing in the US and why it is not going away any time soon.   Come senators, congressmen Please heed the call Don’t stand in the doorway Don’t block up the hall For he that gets hurt Will be he who has stalled”…

USA John G. Singer examines why technological solutions are not a quick fix to overcoming the COVID-19 crisis and how a systems shift is crucial to securing better health outcomes in the long-term.   Strategic failure begins when you turn things over to technologists.   “My 18-year-old daughter, Caroline, responded quickly…

Opinion In the wake of a spate of television advertisements for dietary supplements claiming to offer solutions to the COVID-19 crisis, regular PharmaBoardroom contributor Yacine Sellam argues for the need for a more robust regulatory framework in Algeria and even the creation of a unified FDA-style regulator to counter this threat…

Belgium Serge Kemps, CEO of Nipro Medical Europe, sits down with PharmaBoardroom to shed light on Nipro’s unique corporate culture based on the Japanese concept of ‘sanpro yoshi’. Kemps also explains the importance of Belgium for Nipro, the innovation opportunities in the digitalisation of healthcare, and his strategic priorities since taking…

Medicines for Europe In the wake of the publication of Medicines for Europe’s Lessons Learned from COVID-19 policy paper, Christoph Stoller & Adrian van den Hoven outline the European generics, biosimilar and value-added-medicines industry’s rapid and comprehensive response to the COVID-19 crisis as well as the potential long-term shifts in European pharmaceutical policy…

China Dr Qing Liu, Arctic Vision’s VP for Clinical & Regulatory Affairs, shares her key priorities and the potential for top-line ophthalmological innovations in the Chinese market.   Unmet medical needs in eye care are huge in the Asia markets, and biotech companies will become increasingly important players and innovation drivers…

China Dr Yi (York) Chen, VP for operations and commercial planning at Arctic Vision shares his priorities, his wide experience of ophthalmology product launches in China, and how the company is positioning itself in relation to much larger companies in the Chinese ophthalmology market.   Fundamentally, we are convinced that the…

Novartis In late 2019 Novartis hit the headlines in Belgium after it refused to grant access to its one-off gene therapy Zolgensma® for the ultra-rare muscle-wasting disease spinal muscular atrophy (SMA) to Pia Boehnke, a Belgian child.   With Zolgensma® at that point having not yet been authorised by the European…